CCM
DNA icon

Coldstream Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Coldstream Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-180
Closed -$1.03K – 1713
2025
Q1 		$1.03K Buy
+180
New +$1.83K ﹤0.01% 3182
2023
Q4 		– Sell
-294
Closed -$21.3K – 946
2023
Q3 		$21.3K Buy
+294
New +$23.5K ﹤0.01% 798

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Coldstream Capital Management's DNA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 180 shares — an estimated $1.03K sold.

Coldstream Capital Management first reported a position in DNA in Q3 2023 and held it in 2 quarters. The position peaked at $21.3K in Q3 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 180 Ginkgo Bioworks shares in Q2 2025, an estimated $1.03K.
  • Coldstream Capital Management first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 2 quarters.
  • Coldstream Capital Management's Ginkgo Bioworks position peaked at $21.3K in Q3 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.